Artiva, fresh from Merck pact, raises $120M for NK therapy R&D

Artiva Biotherapeutics has raised $120 million to advance a pipeline of allogeneic natural killer (NK) cell therapies. The Merck-partnered biotech has an unmodified NK cell therapy in the clinic and a clutch of CAR-engineered candidates following close behind.